Free Trial
NASDAQ:HOWL

Werewolf Therapeutics (HOWL) Stock Price, News & Analysis

Werewolf Therapeutics logo
$1.39 -0.01 (-0.71%)
Closing price 04:00 PM Eastern
Extended Trading
$1.40 +0.01 (+0.72%)
As of 06:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Werewolf Therapeutics Stock (NASDAQ:HOWL)

Key Stats

Today's Range
$1.39
$1.44
50-Day Range
$1.02
$1.42
52-Week Range
$0.60
$4.18
Volume
242,364 shs
Average Volume
443,345 shs
Market Capitalization
$62.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.33
Consensus Rating
Buy

Company Overview

Werewolf Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
70th Percentile Overall Score

HOWL MarketRank™: 

Werewolf Therapeutics scored higher than 70% of companies evaluated by MarketBeat, and ranked 298th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Werewolf Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Werewolf Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Werewolf Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Werewolf Therapeutics are expected to decrease in the coming year, from ($1.56) to ($1.92) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Werewolf Therapeutics is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Werewolf Therapeutics is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Werewolf Therapeutics has a P/B Ratio of 0.84. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Werewolf Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    3.99% of the float of Werewolf Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Werewolf Therapeutics has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Werewolf Therapeutics has recently decreased by 28.26%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Werewolf Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Werewolf Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.99% of the float of Werewolf Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Werewolf Therapeutics has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Werewolf Therapeutics has recently decreased by 28.26%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Werewolf Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    Only 2 people have searched for HOWL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Werewolf Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $435,273.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    23.60% of the stock of Werewolf Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    64.84% of the stock of Werewolf Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Werewolf Therapeutics' insider trading history.
Receive HOWL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Werewolf Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HOWL Stock News Headlines

Google did what!?!?
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.
Werewolf Therapeutics, Inc. (HOWL) - Yahoo Finance
See More Headlines

HOWL Stock Analysis - Frequently Asked Questions

Werewolf Therapeutics' stock was trading at $1.48 at the beginning of the year. Since then, HOWL shares have decreased by 6.1% and is now trading at $1.39.

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) announced its earnings results on Thursday, May, 8th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.44) by $0.04.

Werewolf Therapeutics (HOWL) raised $101 million in an initial public offering on Friday, April 30th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, SVB Leerink and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.

Shares of HOWL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Werewolf Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and Jabil (JBL).

Company Calendar

Last Earnings
5/08/2025
Today
7/23/2025
Next Earnings (Estimated)
8/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:HOWL
CIK
1785530
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

High Price Target
$15.00
Low Price Target
$4.00
Potential Upside/Downside
+499.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.67)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$70.51 million
Net Margins
N/A
Pretax Margin
-6,335.17%
Return on Equity
-89.37%
Return on Assets
-54.87%

Debt

Debt-to-Equity Ratio
0.46
Current Ratio
8.09
Quick Ratio
8.09

Sales & Book Value

Annual Sales
$1.88 million
Price / Sales
33.18
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.65 per share
Price / Book
0.84

Miscellaneous

Outstanding Shares
44,870,000
Free Float
34,284,000
Market Cap
$62.37 million
Optionable
Optionable
Beta
0.62
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:HOWL) was last updated on 7/23/2025 by MarketBeat.com Staff
From Our Partners